<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01078909</url>
  </required_header>
  <id_info>
    <org_study_id>PKE LPS</org_study_id>
    <nct_id>NCT01078909</nct_id>
  </id_info>
  <brief_title>Dose Response Effects of Marine Omega-3 Fatty Acids on Inflammation</brief_title>
  <official_title>Dose Response Effects of Marine Omega-3 Fatty Acids on Inflammation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Penn State University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>United States Department of Agriculture (USDA)</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Penn State University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the lowest effective dose of EPA + DHA (300, 600,
      900 and 1,800 mg/day delivered as fish oil supplements) that significantly attenuates the
      inflammatory response to in vivo and ex vivo endotoxin challenge as measured by the
      production over time of several inflammatory markers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Inflammation is an important biological process initiated by the immune system in response to
      injury, irritation or infection. Prolonged or chronic inflammation is involved in the
      etiology of several diseases such as cardiovascular disease (CVD), diabetes, rheumatoid
      arthritis, cancer, and neurodegenerative diseases such as Alzheimer disease. The evidence
      base clearly demonstrates benefits of diet in ameliorating inflammation and reducing the
      burden of chronic disease. With respect to marine-derived omega-3 fatty acids and various
      markers of inflammation related to cardiovascular disease (CVD), both population studies and
      randomized controlled supplementation trials have yielded mixed results.

      Some studies have demonstrated a dose-response relationship between dietary eicosapentaenoic
      acid and docosahexaenoic acid (EPA + DHA) and increased membrane (phospholipid) EPA and DHA.
      Red blood cell (RBC) EPA + DHA content has been proposed as a potential, modifiable marker
      for coronary heart disease (CHD) risk. It is well established that these fatty acids are
      precursors of series-3 prostanoids, thromboxanes, 5-series leukotrienes, and novel lipid
      mediators such as resolvins and protectins that have anti-inflammatory effects. We
      hypothesize that nutritionally-relevant intakes of omega-3 fatty acids are able to blunt the
      usual response to an inflammatory stimulus. We propose to test this hypothesis using both in
      vivo (i.v. endotoxin challenge) and ex vivo (endotoxin-stimulated monocytes) models in a
      6-month, dose-response study with marine-derived omega-3 fatty acid supplements in healthy
      volunteers.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Concentrations of Inflammatory Markers (TNF-alpha and IL-6) Following 5 Months of Treatment</measure>
    <time_frame>5 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Concentrations of CRP Following 5 Months of Treatment</measure>
    <time_frame>5 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Lipid Mediators</measure>
    <time_frame>1, 2, 3 and 5 days post LPS administration</time_frame>
    <description>0 Participants Analyzed; Lipid mediators were unable to be detected therefore there are no data to report.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">125</enrollment>
  <condition>Cardiovascular Disease</condition>
  <condition>Inflammation</condition>
  <arm_group>
    <arm_group_label>300mg Fish Oil (EPA + DHA) Supplement</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>600mg Fish Oil (EPA+DHA) Supplement</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>900mg Fish Oil (EPA + DHA) Supplement</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>1800mg Fish Oil (EPA + DHA) Supplement</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Eicosapentaenoic Acid and Docosahexaenoic Acid (EPA + DHA)</intervention_name>
    <description>Comparison of 4 doses of EPA+DHA on in vivo and ex vivo (monocytes) response to an inflammatory stimulus (endotoxin) following a 6 month supplementation period</description>
    <arm_group_label>300mg Fish Oil (EPA + DHA) Supplement</arm_group_label>
    <arm_group_label>600mg Fish Oil (EPA+DHA) Supplement</arm_group_label>
    <arm_group_label>900mg Fish Oil (EPA + DHA) Supplement</arm_group_label>
    <arm_group_label>1800mg Fish Oil (EPA + DHA) Supplement</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Omega-3 Fatty Acids</other_name>
    <other_name>Fish Oil</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy men and non-pregnant/lactating women between the ages of 20 and 45

          -  BMI &gt;19.9 and &lt;30.0

          -  Able to give written informed consent and willing to comply with all study- related
             procedures.

        Exclusion Criteria:

          -  Previous history of heart disease or diabetes

          -  Renal Insufficiency

          -  Chronic anti-inflammatory use

          -  Systolic blood pressure &lt; 90

          -  Individuals currently using tobacco products or have done so in the previous 30 days

          -  Individuals taking Omega-3 fatty acid supplements or their usual intake of fish is
             greater than 3-4 servings per month.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gordon L Jensen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Penn State University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Penn State University</name>
      <address>
        <city>University Park</city>
        <state>Pennsylvania</state>
        <zip>16802</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 1, 2010</study_first_submitted>
  <study_first_submitted_qc>March 1, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 2, 2010</study_first_posted>
  <results_first_submitted>September 16, 2015</results_first_submitted>
  <results_first_submitted_qc>May 16, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">June 14, 2017</results_first_posted>
  <last_update_submitted>September 29, 2017</last_update_submitted>
  <last_update_submitted_qc>September 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Penn State University</investigator_affiliation>
    <investigator_full_name>Penny Kris-Etherton</investigator_full_name>
    <investigator_title>Distinguished Professor of Nutrition</investigator_title>
  </responsible_party>
  <keyword>Cardiovascular disease</keyword>
  <keyword>Inflammation</keyword>
  <keyword>Fish Oil</keyword>
  <keyword>Omega-3 Fatty Acids</keyword>
  <keyword>LPS</keyword>
  <keyword>Endotoxin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment and screened occured between September 2011 and March 2012 at the Clinical Research Center at Penn State University.</recruitment_details>
      <pre_assignment_details>A computer‐generated randomization scheme was developed in advance. The randomization scheme was stratified by sex and age and used a balanced block size of 5 to ensure even distribution among treatment groups. Using this randomization scheme, eligible participants were assigned to blinded treatments at the baseline visit by the study coordinator.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>300mg Fish Oil (EPA + DHA) Supplement</title>
          <description>Eicosapentaenoic Acid and Docosahexaenoic Acid (EPA + DHA) following a 6 month supplementation period</description>
        </group>
        <group group_id="P2">
          <title>600mg Fish Oil (EPA+DHA) Supplement</title>
          <description>Eicosapentaenoic Acid and Docosahexaenoic Acid (EPA + DHA) following a 6 month supplementation period</description>
        </group>
        <group group_id="P3">
          <title>900mg Fish Oil (EPA + DHA) Supplement</title>
          <description>Eicosapentaenoic Acid and Docosahexaenoic Acid (EPA + DHA) following a 6 month supplementation period</description>
        </group>
        <group group_id="P4">
          <title>1800mg Fish Oil (EPA + DHA) Supplement</title>
          <description>Eicosapentaenoic Acid and Docosahexaenoic Acid (EPA + DHA) following a 6 month supplementation period</description>
        </group>
        <group group_id="P5">
          <title>Placebo</title>
          <description>Eicosapentaenoic Acid and Docosahexaenoic Acid (EPA + DHA) following a 6 month supplementation period</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="25"/>
                <participants group_id="P3" count="25"/>
                <participants group_id="P4" count="25"/>
                <participants group_id="P5" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="24"/>
                <participants group_id="P4" count="24"/>
                <participants group_id="P5" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>300mg Fish Oil (EPA + DHA) Supplement</title>
          <description>Eicosapentaenoic Acid and Docosahexaenoic Acid (EPA + DHA) following a 5 month supplementation period</description>
        </group>
        <group group_id="B2">
          <title>600mg Fish Oil (EPA+DHA) Supplement</title>
          <description>Eicosapentaenoic Acid and Docosahexaenoic Acid (EPA + DHA) following a 5 month supplementation period</description>
        </group>
        <group group_id="B3">
          <title>900mg Fish Oil (EPA + DHA) Supplement</title>
          <description>Eicosapentaenoic Acid and Docosahexaenoic Acid (EPA + DHA) following a 65 month supplementation period</description>
        </group>
        <group group_id="B4">
          <title>1800mg Fish Oil (EPA + DHA) Supplement</title>
          <description>Eicosapentaenoic Acid and Docosahexaenoic Acid (EPA + DHA) following a 5 month supplementation period</description>
        </group>
        <group group_id="B5">
          <title>Placebo</title>
          <description>Eicosapentaenoic Acid and Docosahexaenoic Acid (EPA + DHA) following a 5 month supplementation period</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="23"/>
            <count group_id="B2" value="21"/>
            <count group_id="B3" value="24"/>
            <count group_id="B4" value="24"/>
            <count group_id="B5" value="23"/>
            <count group_id="B6" value="115"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.8" spread="7.2"/>
                    <measurement group_id="B2" value="27.1" spread="7.3"/>
                    <measurement group_id="B3" value="25.8" spread="6.4"/>
                    <measurement group_id="B4" value="26.0" spread="5.9"/>
                    <measurement group_id="B5" value="25.7" spread="6.7"/>
                    <measurement group_id="B6" value="26.1" spread="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="12"/>
                    <measurement group_id="B6" value="55"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="11"/>
                    <measurement group_id="B6" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Concentrations of Inflammatory Markers (TNF-alpha and IL-6) Following 5 Months of Treatment</title>
        <time_frame>5 months</time_frame>
        <population>One individual was removed from the analysis due to having very high RBC EPA+DHA content at study entry (&gt;8%)</population>
        <group_list>
          <group group_id="O1">
            <title>300mg Fish Oil (EPA + DHA) Supplement</title>
          </group>
          <group group_id="O2">
            <title>600mg Fish Oil (EPA+DHA) Supplement</title>
          </group>
          <group group_id="O3">
            <title>900mg Fish Oil (EPA + DHA) Supplement</title>
          </group>
          <group group_id="O4">
            <title>1800mg Fish Oil (EPA + DHA) Supplement</title>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>Mean Concentrations of Inflammatory Markers (TNF-alpha and IL-6) Following 5 Months of Treatment</title>
          <population>One individual was removed from the analysis due to having very high RBC EPA+DHA content at study entry (&gt;8%)</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="23"/>
                <count group_id="O5" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TNF-alpha (pg/mL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" lower_limit="1.3" upper_limit="1.5"/>
                    <measurement group_id="O2" value="1.3" lower_limit="1.1" upper_limit="1.5"/>
                    <measurement group_id="O3" value="1.4" lower_limit="1.2" upper_limit="1.5"/>
                    <measurement group_id="O4" value="1.5" lower_limit="1.2" upper_limit="1.6"/>
                    <measurement group_id="O5" value="1.4" lower_limit="1.1" upper_limit="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-6 (pg/mL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" lower_limit="0.7" upper_limit="1.1"/>
                    <measurement group_id="O2" value="1" lower_limit="0.8" upper_limit="1.2"/>
                    <measurement group_id="O3" value="0.9" lower_limit="0.7" upper_limit="1.1"/>
                    <measurement group_id="O4" value="1" lower_limit="0.8" upper_limit="1.2"/>
                    <measurement group_id="O5" value="0.9" lower_limit="0.7" upper_limit="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Concentrations of CRP Following 5 Months of Treatment</title>
        <time_frame>5 months</time_frame>
        <population>One individual was removed from the analysis due to having very high RBC EPA+DHA content at study entry (&gt;8%)</population>
        <group_list>
          <group group_id="O1">
            <title>300mg Fish Oil (EPA + DHA) Supplement</title>
          </group>
          <group group_id="O2">
            <title>600mg Fish Oil (EPA+DHA) Supplement</title>
          </group>
          <group group_id="O3">
            <title>900mg Fish Oil (EPA + DHA) Supplement</title>
          </group>
          <group group_id="O4">
            <title>1800mg Fish Oil (EPA + DHA) Supplement</title>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>Mean Concentrations of CRP Following 5 Months of Treatment</title>
          <population>One individual was removed from the analysis due to having very high RBC EPA+DHA content at study entry (&gt;8%)</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="23"/>
                <count group_id="O5" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" lower_limit="0.4" upper_limit="1.1"/>
                    <measurement group_id="O2" value="0.5" lower_limit="0.3" upper_limit="0.6"/>
                    <measurement group_id="O3" value="0.6" lower_limit="0.4" upper_limit="1.0"/>
                    <measurement group_id="O4" value="0.6" lower_limit="0.4" upper_limit="0.9"/>
                    <measurement group_id="O5" value="0.5" lower_limit="0.3" upper_limit="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Lipid Mediators</title>
        <description>0 Participants Analyzed; Lipid mediators were unable to be detected therefore there are no data to report.</description>
        <time_frame>1, 2, 3 and 5 days post LPS administration</time_frame>
        <population>Lipid mediators were unable to be detected; Data were not collected.</population>
        <group_list>
          <group group_id="O1">
            <title>300mg Fish Oil (EPA + DHA) Supplement</title>
          </group>
          <group group_id="O2">
            <title>600mg Fish Oil (EPA+DHA) Supplement</title>
          </group>
          <group group_id="O3">
            <title>900mg Fish Oil (EPA + DHA) Supplement</title>
          </group>
          <group group_id="O4">
            <title>1800mg Fish Oil (EPA + DHA) Supplement</title>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>Change in Lipid Mediators</title>
          <description>0 Participants Analyzed; Lipid mediators were unable to be detected therefore there are no data to report.</description>
          <population>Lipid mediators were unable to be detected; Data were not collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>300 mg/d EPA + DHA (Fish Oil) Supplement</title>
        </group>
        <group group_id="E2">
          <title>600 mg/d EPA + DHA (Fish Oil) Supplement</title>
        </group>
        <group group_id="E3">
          <title>900 mg/d EPA + DHA (Fish Oil) Supplement</title>
        </group>
        <group group_id="E4">
          <title>1800 mg/d EPA + DHA (Fish Oil) Supplement</title>
        </group>
        <group group_id="E5">
          <title>0 mg/d EPA + DHA (Placebo)</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Penny Kris-Etherton</name_or_title>
      <organization>The Pennsylvania State University</organization>
      <phone>814-863-2923</phone>
      <email>pmk3@psu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

